YKL-05-099

YKL-05-099 is a small molecule inhibitor of Salt-Inducible Kinases (SIK), specifically targeting SIK1, SIK2, and SIK3. Developed by researchers at the Dana-Farber Cancer Institute, it was initially identified as a tool to potentiate T cell activity in solid tumors but has demonstrated significant efficacy in suppressing the growth of Natural Killer (NK) cell malignancies. The compound works by downregulating STAT5 signaling and inhibiting MYC and E2F target pathways, which are often overactive in aggressive NK-cell lymphomas and leukemias. In preclinical models, YKL-05-099 has shown the ability to reduce the proliferation and viability of human NK lymphoma/leukemia cell lines and improve survival in xenograft models of aggressive NK leukemia.